SCHEMBL207698

SCHEMBL207698

CC(=O)N(C)c1cccs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.44
POLB P06746 2/20 0.44
CASP6 P55212 1/20 0.44
ALDH1A1 P00352 5/20 0.42
HSD17B10 Q99714 3/20 0.42
CES2 O00748 1/20 0.40
CES1 P23141 1/20 0.40
DAO P14920 1/20 0.39
GAA P10253 2/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
GLA P06280 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
RAB9A P51151 5/20 0.36
HDAC1 Q13547 1/20 0.36
TSPO P30536 1/20 0.36
ALOX5 P09917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5353440 0.98 NPC1 (0.43) NPC1POLBCASP6ALDH1A1HSD17B10
SCHEMBL3561735 0.83 DAO (0.43) NPC1POLBALDH1A1HSD17B10CES2
SCHEMBL9850025 0.82 ALOX5 (0.46) NPC1POLBCASP6ALDH1A1HSD17B10
SCHEMBL207697 0.82 MEN1 (0.40) NPC1POLBCASP6ALDH1A1HSD17B10
SCHEMBL8789708 0.79 NPC1 (0.37) NPC1POLBCASP6ALDH1A1HSD17B10
SCHEMBL11057975 0.79 TSHR (0.43) NPC1HSD17B10CES2CES1GAA
SCHEMBL8789670 0.78 ADAM17 (0.36) NPC1POLBCASP6ALDH1A1HSD17B10
SCHEMBL10404784 0.78 DAO (0.36) NPC1POLBCASP6ALDH1A1HSD17B10
SCHEMBL9319667 0.78 ALDH1A1 (0.41) NPC1POLBCASP6ALDH1A1HSD17B10
SCHEMBL2417968 0.77 KMT2A (0.49) NPC1POLBALDH1A1HSD17B10CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-8058440-B2 Process for producing 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-11-15 US disclosed
US-20110054177-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-03 US disclosed
US-7880005-B2 reacting 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine with an alkali metal nitrite in the presence of a reducing agent in an aqueous solution of an acidic compound; hydrolysis; industrial scale DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-01 US disclosed
EP-2266991-A2 Process for producing thiazole derivative Daiichi Sankyo Company, Limited (JP) 2010-12-29 EP disclosed
EP-2266992-A2 Process for producing thiazole derivative Daiichi Sankyo Company, Limited (JP) 2010-12-29 EP disclosed
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-04-22 US disclosed
US-20100076192-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-03-25 US disclosed
US-7678910-B2 Process for producing 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]Pyridine-2-carboxylic acid DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-03-16 US disclosed
US-20090281074-A1 DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM DAIICHI PHARMACEUTICAL CO., LTD (JP) 2009-11-12 US disclosed
US-20070135476-A1 Process for producing thiazole derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
US-20070129371-A1 Novel ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-06-07 US disclosed
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-09 US disclosed
EP-1683800-A1 PROCESS FOR PRODUCING THIAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-07-26 EP disclosed
EP-1577301-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
EP-1577302-A1 NOVEL ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
CN-1153515-A N-heterocyclyl-heteroaryloxyacetamides BAYER AG (DE) 1997-07-02 CN disclosed
EP-0764164-A1 N-HETEROCYCLYL-HETEROARYLOXYACETAMIDES BAYER AG (DE) 1997-03-26 EP disclosed
WO-1995034560-A1 N-HETEROCYCLYL-HETEROARYLOXYACETAMIDES BAYER AKTIENGESELLSCHAFT (DE) 1995-12-21 WO disclosed
WO-1995024395-A1 QUINOLINE DERIVATIVES AS IMMUNOMODULATORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110054177-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID PAH, CA4, TET2 NPC1 4357/4885POLB 2910/4885CASP6 632/4885
US-20070129371-A1 Novel ethylenediamine derivatives C1R, C9, C1S NPC1 3135/4885POLB 906/4885CASP6 982/4885
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES F2, PLAT, MPL NPC1 3353/4885POLB 402/4885CASP6 1166/4885
US-20100076192-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID NOX4, NOX5, NOS2 NPC1 4548/4885POLB 3796/4885CASP6 1064/4885
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X F2, C1S, C9 NPC1 3879/4885POLB 1050/4885CASP6 1214/4885
US-20090281074-A1 DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM C1R, C9, F2 NPC1 3934/4885POLB 1665/4885CASP6 1630/4885
US-20070135476-A1 Process for producing thiazole derivative TALDO1, CYP3A4, DHPS NPC1 1871/4885POLB 2194/4885CASP6 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.